Zogenix (NASDAQ: ZGNX ) shareholders have had a roller coaster ride in 2014, with the share price climbing to almost $5 per share before cratering below $1.70. Tremendous controversy has swirled around Zohydro ER, an opioid painkiller that many fear could be abused.
The company received good news when Massachusetts Governor Deval Patrick's regulations to restrict the drug's usage were overturned by a federal court, and announced further good news that it may have a more tamper-resistant version of the drug out by 2015.
The big question: Has all the negativity been priced in already, or is this stock still one to avoid? In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take.
Leaked: This coming blockbuster will make every biotech -- Zogenix included -- jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.